Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Secretary of Agriculture Brooke Rollins on Wednesday announced a plan to enhance the agency's ability to detect, control and ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Option chain shows key data for Verve Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market ...

Fintel reports that on June 18, 2025, LifeSci Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

Asian shares are mixed and oil prices have dropped Wednesday as investors calmed from the jitters of conflict in the Middle ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Verve Therapeutics VERV in the last three months. The table below provides a snapshot of their ...